The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•21 February 2026•

1 min read

FDA Approves Vanda Pharmaceuticals' BYSANTI for Schizophrenia and Bipolar I

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1The U.S. FDA approved BYSANTI (milsaperidone) as a first-line therapy for manic or mixed episodes associated with bipolar I disorder and for schizophrenia in adults.

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that the U.S. Food and Drug Administration (FDA) has approved its new drug, BYSANTI (milsaperidone). The medication is authorized as a first-line treatment for adults suffering from schizophrenia and manic or mixed episodes associated with bipolar I disorder. BYSANTI is classified as a New Chemical Entity (NCE) and belongs to the class of atypical antipsychotics. This regulatory milestone marks a significant expansion of Vanda's psychiatric portfolio, offering a new therapeutic option for complex mental health conditions. Market analysts view this approval as a major catalyst for the company's long-term revenue growth and stock performance. The successful review underscores the drug's safety and efficacy profile as established in clinical trials.